United Therapeutics UTHR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $274.9M-24.5% | $364.3M+7.6% | $338.7M+9.4% | $309.5M-3.9% | $322.2M+6.9% | ||
| $22.6M-0.9% | $22.8M+4.1% | $21.9M+3.8% | $21.1M+6.6% | $19.8M+0.5% | ||
| $33.9M-13.1% | $39M-0.3% | $39.1M+3.4% | $37.8M+18.9% | $31.8M+17.8% | ||
| $25.9M— | —— | —— | —— | $0+100% | ||
| -$38.2M-173% | $52.5M— | —— | $57.3M+34.2% | $42.7M— | ||
| $40.1M+143% | $16.5M-5.7% | $17.5M+136% | $7.4M-33.9% | $11.2M-3.4% | ||
| -$12.7M-155% | $23.2M-25.6% | $31.2M-32.3% | $46.1M+1,873% | -$2.6M— | ||
| -$27M-127% | $98.2M+246% | -$67.2M-136% | $184.4M+237% | -$134.5M-398% | ||
| -$61.6M— | —— | —— | —— | -$5.3M— | ||
| $463.3M+33.8% | $346.2M-38.4% | $562.1M+193% | $191.7M-58.4% | $461.2M+35.2% | ||
| $100.8M-41.7% | $172.9M-17.9% | $210.5M+238% | $62.2M-17.0% | $74.9M-13.6% | ||
| $701.7M+34.9% | $520.3M+34.8% | $385.9M-78.6% | $1.81B+161% | $692.3M+44.7% | ||
| $1.31B— | $0-100% | $596M-52.9% | $1.27B— | $0— | ||
| $743.7M+427% | -$227.6M— | —— | -$299.9M-82.1% | -$164.7M— | ||
| $1.5B— | $0-100% | $1B— | $0— | $0— | ||
| $0— | —— | —— | $400M+300% | $100M0.0% | ||
| $68.3M-31.0% | $99M+146% | $40.2M+122% | $18.1M+9.0% | $16.6M-35.4% | ||
| $58.3M+9,617% | $600K+20.0% | $500K+150% | $200K-98.7% | $15.3M+5,000% | ||
| -$1.48B— | $0+100% | -$956M-381% | -$198.6M-112% | -$93.8M-25.6% | ||
| -$277.4M— | —— | -$253M+17.5% | -$306.8M-251% | $202.7M+41.5% | ||
| $1.9M-5.0% | $2M+5.3% | $1.9M-54.8% | $4.2M-22.2% | $5.4M-25.0% | ||
| $1.5M-97.1% | $51M+507% | $8.4M-96.7% | $253.4M+50,580% | $500K-99.6% | ||
| -$32M-195% | $33.6M+33,500% | $100K+101% | -$9.9M-141% | -$4.1M-258% | ||
| $5.7M— | —— | $5.7M+850% | $600K-93.5% | $9.2M+53.3% | ||
| $25M0.0% | $25M-16.7% | $30M— | $0— | $0-100% | ||
| $269M-44.6% | $485.5M+166% | $182.5M-40.0% | $304.2M-50.3% | $611.7M+28.0% | ||
| $1.31B— | $0-100% | $596M-52.9% | $1.27B— | $0— | ||
| $5.6M— | —— | $4.3M— | —— | $4.9M— | ||
| $99.6M+313% | $24.1M-7.3% | $26M+36.8% | $19M-59.7% | $47.2M— | ||
| $1.5M-97.1% | $51M+507% | $8.4M-96.7% | $253.4M+50,580% | $500K-99.6% | ||
| $8.4M— | —— | $5.3M— | $0— | $0— | ||
| $362.5M+109% | $173.3M-50.7% | $351.6M+172% | $129.5M-66.5% | $386.3M+51.8% | ||
| $362.5M+109% | $173.3M-50.7% | $351.6M+172% | $129.5M-66.5% | $386.3M+51.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does United Therapeutics generate?
- United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
- What is United Therapeutics's free cash flow?
- After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
- Where does United Therapeutics's cash flow data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
